Conference
First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).
Abstract
432
Background: FDA modified the label for the use of 1st-line pembrolizumab or atezolizumab therapy to PD-L1 high cisplatin-ineligible or platinum-ineligible UC patients (pts) regardless of PD-L1 expression. However, the outcomes when using PD1/PD-L1 inhibitors for platinum-ineligible pts are unclear. We conducted a retrospective study to evaluate clinical outcomes with first-line PD1/PD-L1 inhibitors for platinum-ineligible …
Authors
Agarwal A; Pond GR; Drakaki A; Lee J-L; Bilen MA; Di Lorenzo G; Grivas P; Ornstein MC; Barata PC; Gupta S
Volume
37
Pagination
pp. 432-432
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 1, 2019
DOI
10.1200/jco.2019.37.7_suppl.432
Conference proceedings
Journal of Clinical Oncology
Issue
7_suppl
ISSN
0732-183X